An Open-label, Multi-center, Phase 2 Basket Study to Assess Efficacy, Safety and Pharmacokinetics of Iptacopan (LNP023) in Participants With Autoimmune Benign Hematological Disorders
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Iptacopan (Primary) ; Hib vaccine conjugate; Meningococcal vaccine group B OMV Novartis; Meningococcal vaccine groups A C Y W-135 conjugate; Pneumococcal vaccine
- Indications Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 03 Jun 2024 Status changed from active, no longer recruiting to discontinued.
- 29 May 2024 This trial has been Discontinued in Germany, according to European Clinical Trials Database record.
- 08 May 2024 This study has been completed in Germany, according to European Clinical Trials Database record.